银屑病治疗靶点及其药物研发进展

被引：53

作者：

陈明 ^{[1
]}

钟杰敏 ^{[1
]}

刘冠萍 ^{[1
]}

李柏霖 ^{[1
]}

陈新 ^{[2
]}

机构：

[1] 广西梧州制药(集团)有限公司

[2] 四川大学生物治疗国家重点实验室

来源：

中国医院药学杂志 | 2015年 / 35卷 / 09期

关键词：

银屑病; 自身免疫; TNF-α; PDE4; JAK; 白介素; 进展;

D O I：

10.13286/j.cnki.chinhosppharmacyj.2015.09.21

中图分类号：

R758.63 [牛皮癣（银屑病）];

学科分类号：

100227 [皮肤病学];

摘要：

银屑病的发病机制未能完全阐明,近年来大量的实验和临床研究证实,银屑病可能是T细胞介导的自身免疫性疾病。这一发病过程涉及了很多靶点的激活,T细胞增殖和细胞因子的作用。目前,基于这些靶点研发治疗银屑病的新药已取得了长足的进展,本文就近年来银屑病靶向药物研究进展作一综述,为开发新的靶向药物提供参考。

引用

页码：846 / 850

页数：5

共 10 条

[1]

Accumulation of FLT3+ CD11c+ dendritic cells in psoriatic lesions and the anti-psoriatic effect of a selective FLT3 inhibitor [J].

Yan, Heng-Xiu ;

Li, Wei-Wei ;

Zhang, Yan ;

Wei, Xia-Wei ;

Fu, Li-Xin ;

Shen, Guo-Bo ;

Yin, Tao ;

Li, Xiu-Ying ;

Shi, Hua-Shan ;

Wan, Yang ;

Zhang, Qing-Yin ;

Li, Jiong ;

Yang, Sheng-Yong ;

Wei, Yu-Quan .

IMMUNOLOGIC RESEARCH, 2014, 60 (01) :112-126

[2]

Randomized, double-blind, placebo-controlled, multiple-dose study of the safety, tolerability and pharmacokinetics of benvitimod, a candidate drug for the treatment of psoriasis [J].

Zhao, L. ;

Chen, X. ;

Cai, L. ;

Zhang, C. ;

Wang, Q. ;

Jing, S. ;

Chen, G. ;

Li, J. ;

Zhang, J. ;

Fang, Y. .

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2014, 39 (04) :418-423

[3]

Psoriasis prevalence among adults in the United States [J].

Rachakonda, Tara D. ;

Schupp, Clayton W. ;

Armstrong, April W. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (03) :512-516

[4]

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis [J].

Ports, W. C. ;

Khan, S. ;

Lan, S. ;

Lamba, M. ;

Bolduc, C. ;

Bissonnette, R. ;

Papp, K. .

BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 (01) :137-145

[5]

The role of JAK–STAT signaling in adipose tissue function.[J].Allison J. Richard;Jacqueline M. Stephens.BBA - Molecular Basis of Disease.2013,

[6]

Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal [J].

Spuls, Ph. I. ;

Hooft, L. .

BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (04) :710-713

[7]

Synthetic staurosporines via a ring closing metathesis strategy as potent JAK3 inhibitors and modulators of allergic responses [J].

Wilson, Lawrence J. ;

Malaviya, Ravi ;

Yang, Cangming ;

Argentieri, Rochelle ;

Wang, Bingbing ;

Chen, Xin ;

Murray, William V. ;

Cavender, Druie .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (12) :3333-3338

[8]

Emerging treatments in the management of psoriasis: biological targeting with ustekinumab.[J].Marina Papoutsaki.Clinical; Cosmetic and Investigational Dermatology.2009, defa

[9]

The PKC inhibitor AEB071 may be a therapeutic option for psoriasis [J].

Skvara, Hans ;

Dawid, Markus ;

Kleyn, Elise ;

Wolff, Barbara ;

Meingassner, Josef G. ;

Knight, Hilary ;

Dumortier, Thomas ;

Kopp, Tamara ;

Fallahi, Nasanin ;

Stary, Georg ;

Burkhart, Christoph ;

Grenet, Olivier ;

Wagner, Juergen ;

Hijazi, Youssef ;

Morris, Randall E. ;

McGeown, Claire ;

Rordorf, Christiane ;

Griffiths, Christopher E. M. ;

Stingl, Georg ;

Jung, Thomas .

JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (09) :3151-3159

[10]

Dimethyl fumarate; a small molecule drug for psoriasis; inhibits Nuclear Factor-κB and reduces myocardial infarct size in rats.[J].Silvia Meili-Butz;Thomas Niermann;Elizaveta Fasler-Kan;Vania Barbosa;Nicole Butz;Dietlinde John;Marijke Brink;Peter T. Buser;Christian E. Zaugg.European Journal of Pharmacology.2008, 1

← 1 →